Kezar Life Sciences

Historical price data

Kezar Life Sciences is a public biotechnology company developing first-in-class small molecule therapies for chronic diseases, with a primary focus on autoimmune and liver conditions. The company's strategy leverages two distinct technology platforms: selective immunoproteasome inhibition and Sec61 pathway targeting, designed to modulate disease-driving pathways with greater precision than standard immunosuppressants. Its most advanced program, zetomipzomib, is in clinical development for autoimmune hepatitis, following a strategic pivot after discontinuing earlier oncology efforts. Kezar operates as a lean, focused organization navigating the high-risk, high-reward landscape of novel mechanism drug development.

Two novel small molecule platforms: 1) Selective immunoproteasome inhibition for immune modulation in autoimmune diseases, and 2) Sec61 translocon targeting to modulate protein secretion, with preclinical assets recently divested.

In autoimmune hepatitis, zetomipzomib competes against entrenched generic corticosteroids and immunomodulators, as well as other novel mechanisms in development. Its primary differentiation is its first-in-class, selective immunoproteasome inhibitor mechanism designed for immune modulation, coupled with oral administration, but it must demonstrate clear superiority in efficacy or safety to change clinical practice.